Angiotensin-converting enzyme-2 (ACE2) has been established as the functional host receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the current devastating worldwide pandemic of coronavirus disease 2019 (COVID-19). ACE2 is abundantly expressed in a variety of cells residing in many different human organs. In human physiology, ACE2 is a pivotal counter-regulatory enzyme to ACE by the breakdown of angiotensin II, the central player in the renin-angiotensin-aldosterone system (RAAS) and the main substrate of ACE2. Many factors have been associated with both altered ACE2 expression and COVID-19 severity and progression, including age, sex, ethnicity, medication and several co-morbidities, such as cardiovascular disease and metabolic syndrome. Although ACE2 is widely distributed in various human tissues and many of its determinants have been well recognised, ACE2-expressing organs do not equally participate in COVID-19 pathophysiology, implying that other mechanisms are involved in orchestrating cellular infection resulting in tissue damage. Reports of pathologic findings in tissue specimens of COVID-19 patients are rapidly emerging and confirm the established role of ACE2 expression and activity in disease pathogenesis. Identifying pathologic changes caused by SARS-CoV-2 infection is crucially important as it has major implications for understanding COVID-19 pathophysiology and the development of evidence-based treatment strategies. Currently, many interventional strategies are being explored in ongoing clinical trials, encompassing many drug classes and strategies, including antiviral drugs, biological response modifiers and RAAS inhibitors. Ultimately, prevention is key to combat COVID-19 and appropriate measures are being taken accordingly, including development of effective vaccines. In this review, we describe the role of ACE2 in COVID-19 pathophysiology, including factors influencing ACE2 expression and activity in relation to COVID-19 severity. In addition, we discuss the relevant pathological changes resulting from SARS-CoV-2 infection. Finally, we highlight a selection of potential treatment modalities for COVID-19. This article is protected by copyright. All rights reserved.
Keywords: Angiotensin-converting enzyme-2 (ACE2); Coronavirus disease 2019 (COVID-19); Organ involvement; Pathology; Pathophysiology; Renin-angiotensin-aldosterone system (RAAS); Risk factors; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Treatment.
This article is protected by copyright. All rights reserved.
Focus on Receptors for Coronaviruses with Special Reference to Angiotensin-converting Enzyme 2 as a Potential Drug Target - A Perspective.Endocr Metab Immune Disord Drug Targets. 2020 Apr 27. doi: 10.2174/1871530320666200427112902. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2020. PMID: 32338224
Counter-regulatory 'Renin-Angiotensin' System-based Candidate Drugs to Treat COVID-19 Diseases in SARS-CoV-2-infected patients.Infect Disord Drug Targets. 2020 May 17. doi: 10.2174/1871526520666200518073329. Online ahead of print. Infect Disord Drug Targets. 2020. PMID: 32418532
Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor.Pharmacol Res. 2020 Apr 14;157:104833. doi: 10.1016/j.phrs.2020.104833. Online ahead of print. Pharmacol Res. 2020. PMID: 32302706 Free PMC article. Review.
ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome.J Microbiol Immunol Infect. 2020 May 6;53(3):425-35. doi: 10.1016/j.jmii.2020.04.015. Online ahead of print. J Microbiol Immunol Infect. 2020. PMID: 32414646 Free PMC article.
Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.J Med Virol. 2020 Mar 27. doi: 10.1002/jmv.25785. Online ahead of print. J Med Virol. 2020. PMID: 32221983 Review.